GlassScriptPhysician profile
Tracy A Karolyi
NPI 1609868710
$3,958.46
in general payments reported to CMS, 2019-2025
26 companies · $659 in 2025
The $659 reported for 2025 was more than what 96% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $792 · 2020: $239 · 2021: $201 · 2022: $357 · 2023: $959 · 2024: $751 · 2025: $659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,369.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $559.96 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Glaxosmithkline, LLC. | $515.56 | 2019-2025 | Bexsero, Penmenvy, Menveo |
| Ironshore Pharmaceuticals INC. | $485.81 | 2019-2024 | Jornay Pm |
| Corium, LLC | $436.93 | 2022-2025 | Azstarys |
| Pfizer INC. | $355.81 | 2019-2025 | |
| Kaleo, INC. | $324.13 | 2019-2024 | Auvi-Q |
| Neos Therapeutics, LP | $215.89 | 2019-2025 | Cotempla Xr-Odt, Adzenys Xr-Odt |
| Phadia US INC. | $135.90 | 2019-2025 | Immunocap |
| Tris Pharma INC | $131.89 | 2020-2024 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $125.96 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $112.38 | 2022-2025 | Qelbree, Qelbree |
| Astrazeneca Pharmaceuticals LP | $111.89 | 2020-2024 | Flumist Quadrivalent |
| Sanofi Pasteur INC. | $110.33 | 2024-2025 | |
| Vertical Pharmaceuticals, LLC | $55.69 | 2024-2025 | Relexxii |
| Sobi, INC | $43.28 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $33.73 | 2025 | Jornay Pm |
| Avion Pharmaceuticals | $31.15 | 2023 | Methylphenidate Hydrochloride |
| Adlon Therapeutics L.P. | $26.73 | 2019-2020 | |
| Pacira Pharmaceuticals Incorporated | $23.54 | 2024 | Zilretta, Exparel, Iovera |
| Novartis Pharmaceuticals Corporation | $20.69 | 2019 | |
| Aytu Biopharma, INC. | $19.35 | 2024 | Karbinal |
| Roche Diagnostics Corporation | $18.64 | 2019 | |
| Rhythm Pharmaceuticals, INC. | $17.89 | 2025 | Imcivree |
| Advanced Respiratory, INC | $15.91 | 2019 | |
| Novo Nordisk INC | $15.81 | 2024 | Wegovy |
| Seqirus USA INC | $13.61 | 2024 | Flucelvax |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Karolyi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.